Research Papers:

Post-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells

Kevin Brasseur, François Fabi, Pascal Adam, Sophie Parent, Laurent Lessard and Eric Asselin _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:36971-36987. https://doi.org/10.18632/oncotarget.9235

Metrics: PDF 988 views  |   HTML 1873 views  |   ?  


Kevin Brasseur1, François Fabi1, Pascal Adam1, Sophie Parent1, Laurent Lessard1, Eric Asselin1

1Research Group in Cellular Signaling, Department of Medical Biology, Université du Québec à Trois-Rivières, Trois-Rivières, Québec G9A 5H7, Canada

Correspondence to:

Eric Asselin, email: [email protected]

Keywords: Par-4, PI3K, MAPK, proteasome, gynaecological cancers

Received: December 17, 2015     Accepted: April 24, 2016     Published: May 9, 2016


We recently reported the caspase3-dependent cleavage of Par-4 resulting in the accumulation of a 25kDa cleaved-Par-4 (cl-Par-4) fragment and we investigated in the present study the mechanisms regulating this fragment using cl-Par-4-expressing stable clones derived from ovarian and endometrial cancer cell lines.

Cl-Par-4 protein was weakly express in all stable clones despite constitutive expression. However, upon cisplatin treatment, cl-Par-4 levels increased up to 50-fold relative to baseline conditions. Treatment of stable clones with proteasome and translation inhibitors revealed that cisplatin exposure might in fact protect cl-Par-4 from proteasome-dependent degradation. PI3K and MAPK pathways were also implicated as evidenced by an increase of cl-Par-4 in the presence of PI3K inhibitors and a decrease using MAPK inhibitors. Finally using bioinformatics resources, we found diverse datasets showing similar results to those we observed with the proteasome and cl-Par-4 further supporting our data.

These new findings add to the complex mechanisms regulating Par-4 expression and activity, and justify further studies addressing the biological significance of this phenomenon in gynaecological cancer cells.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9235